Panel Discussion: From Broad Depletion to Targeted Precision: Minimizing Unintended Immune- Consequences

Time: 12:30 pm
day: Conference Day Two

Details:

• Examine challenges and mistakes from the past with myeloid depletion strategies and the consequences of non-specific targeting
• Explore emerging techniques that allow selective modulation of pathogenic myeloid subsets while preserving protective populations
• Learn how improved targeting can reduce systemic toxicity and improve therapeutic index

Speakers:

Anna Galkin Dr. Anna Galkin is the Chief Scientific Officer at Axelia Oncology, where she leads efforts to develop novel immunotherapies that reprogram macrophages for anti-tumor activity. Read more

Haitao Guo Dr. Haitao Guo is a dedicated scientist with over a decade of experience in the study of infectious and inflammatory diseases. Currently serving as a Read more

Tatiana Novobrantseva Dr. Tatiana Novobrantseva is Chief Scientific Officer at NextPoint Therapeutics, leading research in cancer immunotherapy. She previously held senior roles at Moderna and co-founded Verseau Read more